The Phase II study was designed to test the effectiveness of Lymphoseek in identifying lymphatic tissue and to evaluate the drug safety of the compound. The pathology results of the trial determined that Lymphoseek accurately identified lymphatic tissue in 99% of the tissue identified by the drug. Further the pathology evaluation of the lymph nodes identified by Lymphoseek confirmed the presence of tumor in 22.4% of the melanoma patients and 22.6% of the breast cancer patients.
David Bupp, Neoprobe’s president and CEO, said: “We are awaiting clearance from the appropriate regulatory agencies and the investigational sites to commence enrollment in the first of our two planned Phase III studies, which will be conducted in patients with either melanoma or breast cancer.”